Vitamin D in Cutaneous T-Cell Lymphoma
Cutaneous T-cell lymphoma (CTCL) is characterized by the proliferation of malignant T cells in inflamed skin lesions. Mycosis fungoides (MF)—the most common variant of CTCL—often presents with skin lesions around the abdomen and buttocks (“bathing suit” distribution), i.e., in skin areas devoid of s...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-03-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/13/6/503 |
| _version_ | 1797241663963267072 |
|---|---|
| author | August-Witte Feentved Ødum Carsten Geisler |
| author_facet | August-Witte Feentved Ødum Carsten Geisler |
| author_sort | August-Witte Feentved Ødum |
| collection | DOAJ |
| description | Cutaneous T-cell lymphoma (CTCL) is characterized by the proliferation of malignant T cells in inflamed skin lesions. Mycosis fungoides (MF)—the most common variant of CTCL—often presents with skin lesions around the abdomen and buttocks (“bathing suit” distribution), i.e., in skin areas devoid of sun-induced vitamin D. For decades, sunlight and vitamin D have been connected to CTCL. Thus, vitamin D induces apoptosis and inhibits the expression of cytokines in malignant T cells. Furthermore, CTCL patients often display vitamin D deficiency, whereas phototherapy induces vitamin D and has beneficial effects in CTCL, suggesting that light and vitamin D have beneficial/protective effects in CTCL. Inversely, vitamin D promotes T helper 2 (Th2) cell specific cytokine production, regulatory T cells, tolerogenic dendritic cells, as well as the expression of immune checkpoint molecules, all of which may have disease-promoting effects by stimulating malignant T-cell proliferation and inhibiting anticancer immunity. Studies on vitamin D treatment in CTCL patients showed conflicting results. Some studies found positive effects, others negative effects, while the largest study showed no apparent clinical effect. Taken together, vitamin D may have both pro- and anticancer effects in CTCL. The balance between the opposing effects of vitamin D in CTCL is likely influenced by treatment and may change during the disease course. Therefore, it remains to be discovered whether and how the effect of vitamin D can be tilted toward an anticancer response in CTCL. |
| first_indexed | 2024-04-24T18:26:55Z |
| format | Article |
| id | doaj.art-71d9babbfd984748ad4f1d34c995a159 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-04-24T18:26:55Z |
| publishDate | 2024-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-71d9babbfd984748ad4f1d34c995a1592024-03-27T13:30:36ZengMDPI AGCells2073-44092024-03-0113650310.3390/cells13060503Vitamin D in Cutaneous T-Cell LymphomaAugust-Witte Feentved Ødum0Carsten Geisler1The LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, DenmarkThe LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, DenmarkCutaneous T-cell lymphoma (CTCL) is characterized by the proliferation of malignant T cells in inflamed skin lesions. Mycosis fungoides (MF)—the most common variant of CTCL—often presents with skin lesions around the abdomen and buttocks (“bathing suit” distribution), i.e., in skin areas devoid of sun-induced vitamin D. For decades, sunlight and vitamin D have been connected to CTCL. Thus, vitamin D induces apoptosis and inhibits the expression of cytokines in malignant T cells. Furthermore, CTCL patients often display vitamin D deficiency, whereas phototherapy induces vitamin D and has beneficial effects in CTCL, suggesting that light and vitamin D have beneficial/protective effects in CTCL. Inversely, vitamin D promotes T helper 2 (Th2) cell specific cytokine production, regulatory T cells, tolerogenic dendritic cells, as well as the expression of immune checkpoint molecules, all of which may have disease-promoting effects by stimulating malignant T-cell proliferation and inhibiting anticancer immunity. Studies on vitamin D treatment in CTCL patients showed conflicting results. Some studies found positive effects, others negative effects, while the largest study showed no apparent clinical effect. Taken together, vitamin D may have both pro- and anticancer effects in CTCL. The balance between the opposing effects of vitamin D in CTCL is likely influenced by treatment and may change during the disease course. Therefore, it remains to be discovered whether and how the effect of vitamin D can be tilted toward an anticancer response in CTCL.https://www.mdpi.com/2073-4409/13/6/503CTCLvitamin Dpathogenesistreatment |
| spellingShingle | August-Witte Feentved Ødum Carsten Geisler Vitamin D in Cutaneous T-Cell Lymphoma Cells CTCL vitamin D pathogenesis treatment |
| title | Vitamin D in Cutaneous T-Cell Lymphoma |
| title_full | Vitamin D in Cutaneous T-Cell Lymphoma |
| title_fullStr | Vitamin D in Cutaneous T-Cell Lymphoma |
| title_full_unstemmed | Vitamin D in Cutaneous T-Cell Lymphoma |
| title_short | Vitamin D in Cutaneous T-Cell Lymphoma |
| title_sort | vitamin d in cutaneous t cell lymphoma |
| topic | CTCL vitamin D pathogenesis treatment |
| url | https://www.mdpi.com/2073-4409/13/6/503 |
| work_keys_str_mv | AT augustwittefeentvedødum vitamindincutaneoustcelllymphoma AT carstengeisler vitamindincutaneoustcelllymphoma |